S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
NASDAQ:AXON

Axon Enterprise - AXON Stock Forecast, Price & News

$125.75
+2.46 (+2.00%)
(As of 10/6/2022 09:46 AM ET)
Add
Compare
Today's Range
$123.56
$125.86
50-Day Range
$110.65
$133.23
52-Week Range
$82.49
$209.00
Volume
42 shs
Average Volume
389,737 shs
Market Capitalization
$8.94 billion
P/E Ratio
64.49
Dividend Yield
N/A
Price Target
$164.22

Axon Enterprise MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
33.2% Upside
$164.22 Price Target
Short Interest
Healthy
2.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Axon Enterprise in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$142,886 Sold Last Quarter
Proj. Earnings Growth
56.41%
From $0.39 to $0.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Industrial Products Sector

68th out of 178 stocks

Ordnance & Accessories, Except Vehicles & Guided Missiles Industry

1st out of 6 stocks

AXON stock logo

About Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Receive AXON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axon Enterprise and its competitors with MarketBeat's FREE daily newsletter.

AXON Stock News Headlines

AXON Crosses Above Key Moving Average Level
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery
Investors constantly hear that lithium is the key to powering our transition to electric vehicles and clean energy. Truth is, switching from gas-powered isn't possible without massive amounts of graphite. But America hasn't produced any graphite since the 1950s. Now, a little-known exploration company has defined America's largest high-quality graphite deposit near Nome, Alaska.
Axon Appoints Andrea James as Chief Communications Officer
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery
Investors constantly hear that lithium is the key to powering our transition to electric vehicles and clean energy. Truth is, switching from gas-powered isn't possible without massive amounts of graphite. But America hasn't produced any graphite since the 1950s. Now, a little-known exploration company has defined America's largest high-quality graphite deposit near Nome, Alaska.
Why Axon Stock Is Still a Buy Today
Axonics: Medical Devices Play
Why Axon Is (Still) a Top Stock
See More Headlines
Receive AXON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axon Enterprise and its competitors with MarketBeat's FREE daily newsletter.

AXON Company Calendar

Last Earnings
8/09/2022
Today
10/06/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Ordnance & accessories, except vehicles & guided missiles
Sub-Industry
Systems Software
Current Symbol
NASDAQ:AXON
Employees
2,992
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$164.22
High Stock Price Forecast
$232.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+30.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-60,020,000.00
Pretax Margin
10.19%

Debt

Sales & Book Value

Annual Sales
$863.38 million
Book Value
$15.30 per share

Miscellaneous

Free Float
66,174,000
Market Cap
$8.94 billion
Optionable
Optionable
Beta
0.62

Key Executives

  • Mr. Patrick W. SmithMr. Patrick W. Smith (Age 51)
    Co-Founder, CEO & Director
    Comp: $33.12k
  • Mr. Luke S. LarsonMr. Luke S. Larson (Age 41)
    Pres (Leave of Absence)
    Comp: $828.01k
  • Mr. Joshua M. IsnerMr. Joshua M. Isner (Age 36)
    Chief Operating Officer
    Comp: $2.48M
  • Mr. Jeffrey C. KuninsMr. Jeffrey C. Kunins (Age 47)
    Chief Product Officer & Exec. VP of Software
    Comp: $753.02k
  • Mr. Jim Zito (Age 41)
    Interim CFO & Corp. Controller
  • Mr. Jenner Holden
    Chief Information Security Officer
  • Ms. Andrea Susan James
    Sr. VP of Investor Relations & Corp. Strategy
  • Mr. Isaiah Fields
    Corp. Sec. & Chief Legal Officer
  • Corinne Clark
    PR Mang.
  • Ms. Elizabeth Hart
    Sr. VP of People Operations













AXON Stock - Frequently Asked Questions

Should I buy or sell Axon Enterprise stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXON shares.
View AXON analyst ratings
or view top-rated stocks.

What is Axon Enterprise's stock price forecast for 2022?

9 Wall Street research analysts have issued 1 year target prices for Axon Enterprise's shares. Their AXON share price forecasts range from $120.00 to $232.00. On average, they anticipate the company's stock price to reach $164.22 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price.
View analysts price targets for AXON
or view top-rated stocks among Wall Street analysts.

How have AXON shares performed in 2022?

Axon Enterprise's stock was trading at $157.00 at the start of the year. Since then, AXON shares have decreased by 21.5% and is now trading at $123.29.
View the best growth stocks for 2022 here
.

When is Axon Enterprise's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our AXON earnings forecast
.

How were Axon Enterprise's earnings last quarter?

Axon Enterprise, Inc. (NASDAQ:AXON) announced its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.62. The biotechnology company earned $285.61 million during the quarter, compared to analyst estimates of $258.96 million. Axon Enterprise had a net margin of 14.20% and a trailing twelve-month return on equity of 12.57%. The firm's revenue was up 30.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.72) EPS.

What guidance has Axon Enterprise issued on next quarter's earnings?

Axon Enterprise updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.07 billion-$1.12 billion, compared to the consensus revenue estimate of $1.27 billion.

What other stocks do shareholders of Axon Enterprise own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

When did Axon Enterprise IPO?

(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Axon Enterprise's stock symbol?

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Who are Axon Enterprise's major shareholders?

Axon Enterprise's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Moody National Bank Trust Division (0.03%). Insiders that own company stock include Adriane M Brown, Caitlin Elizabeth Kalinowski, Hadi Partovi, Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Mark W Kroll, Matthew R Mcbrady, Matthew R Mcbrady and Patrick W Smith.
View institutional ownership trends
.

How do I buy shares of Axon Enterprise?

Shares of AXON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axon Enterprise's stock price today?

One share of AXON stock can currently be purchased for approximately $123.29.

How much money does Axon Enterprise make?

Axon Enterprise (NASDAQ:AXON) has a market capitalization of $8.76 billion and generates $863.38 million in revenue each year. The biotechnology company earns $-60,020,000.00 in net income (profit) each year or $1.95 on an earnings per share basis.

How many employees does Axon Enterprise have?

The company employs 2,992 workers across the globe.

How can I contact Axon Enterprise?

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The official website for the company is www.axovant.com. The biotechnology company can be reached via phone at (480) 991-0797, via email at ir@axon.com, or via fax at 480-991-0791.

This page (NASDAQ:AXON) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.